Published Fri, 30 Nov 2018 11:58:26 -0500 on Seeking Alpha
Actionable Conclusions (1-10): Analysts Projected 14.7% To 40.7% Net Gains For Top Ten Healthcare WallStars By November 2019
Five of ten top dividend-yielding Healthcare stocks were verified as being among the top ten gainers for the coming year based on broker 1-year target prices. (They are tinted gray in the chart above). Thus, this yield-based forecast for Healthcare WallStars as graded by Wall St. proved 50% accurate.
Projections based on estimated dividend amounts from $1000 invested in the ten highest yielding stocks and the aggregate one year analyst mean target prices for those stocks as reported by YCharts produced the 2019 data. Note: one year target prices from one analyst were not applied (n/a). Ten probable profit-generating trades to 2019 were:
Allergan (AGN) was projected to net $407.33 based on dividends, plus a median target price estimate from twenty-three analysts, less broker fees. The Beta number showed this estimate subject to volatility 37% more than the market as a whole.
Gilead (GILD) was projected to net $267.47, based on median target price estimates from twenty-seven analysts plus dividends, less broker fees. The Beta number showed this estimate subject to volatility 1% over the market as a whole.
Royal Philips NV (PHG) was projected to net $251.49 based on dividends, plus the median of target price estimates from three analysts, less broker fees. The Beta number showed this estimate subject to volatility 26% more than the market as a... Read more
|Stock name||Last trade||P/E||Earnings/Share||Dividend/Share||Dividend yield|
|OWENS & MINOR||7.52||0.0||-2.57||0.30||4.08|
|KONINKLIJKE PHILIPS ELECTRONICS||35.06||22.0||1.59||0.80||2.28|
|FRESENIUS MEDICAL CARE||34.23||9.0||3.79||0.43||1.25|
Older articles featuring Glaxosmithkline (GSK):5%+ Dividend Yield Portfolio: Beating The Market 2 Of The Last 3 Years (December 2018 Review)
5%+ Dividend Yield Portfolio: Profiting From A Return To Normal (October 2018 Review)
Bert's October Dividend Income Summary
5%+ Dividend Yield Portfolio: Playing Offense, Not Running Scared (October 2018 Review)
5%+ Dividend Yield Portfolio: Ignore The Political Circus (Sep 2018 Review)
First Quarterly Update - Steve's Dividend Portfolio And Strategy For Replacing My Salary With Dividend Income
5%+ Dividend Yield Portfolio: Foreign Markets Disappointing You Again? (August 2018 Review)
5%+ Dividend Yield Portfolio: Sticking To The Plan (July 2018 Review)
GlaxoSmithKline: Dividend Safe For Now
4 Safe Blue Chips With 5%+ Dividend Yields